Children as young as 4 years of age may choose to take chewable montelukast tablets on a long-term basis under the supervision of a physician. Montelukast is a clinically used leukotriene receptor inhibitor. It is indicated for the prophylaxis and long-term treatment of asthma in children 2 to 14 years of age, including the prevention of daytime and nighttime asthma symptoms, the treatment of aspirin-sensitive asthmatics, and the prevention of exercise-induced bronchoconstriction. Relief of symptoms caused by seasonal allergic rhinitis and perennial allergic rhinitis in children aged 2 to 14 years. The onset of action of this product is a chronic process and usually requires long-term administration. It is generally well tolerated and adverse effects are mild and usually do not require discontinuation of therapy. Children’s drugs need to pay attention to the dosage of medication, need to be under the guidance of clinicians, do not change or adjust the dosage of medication without authorization.